Tyrosine
GET
/api/v1/drug/tyrosineMechanism of action
Sourced from openFDAMechanism-of-action class: Biological Macromolecular Activity.
Indications
Sourced from openFDA- Slimming effect, water retention.
Dosage & administration
Sourced from openFDASUGGESTED DOSAGE One dropper under tongue two times daily. Acute symptoms ½ dropper under tongue every 30 minutes for two hours.
Warnings & precautions
Sourced from openFDAUse only if cap seal is unbroken. If pregnant or breastfeeding, ask a healthcare professional before use. Keep this and all medication out of the reach of children.
Approval history
Sourced from openFDA- Jul 20, 1984NDANDA019018B Braun
- Aug 23, 1984NDANDA018931Baxter Hlthcare
- Sep 6, 1985NDANDA019398Otsuka Icu Medcl
- Oct 17, 1986NDANDA019492Otsuka Icu Medcl
- Mar 26, 1997NDANDA020678Baxter Hlthcare
- Sep 29, 1997NDANDA020734Baxter Hlthcare
- Aug 26, 1998NDANDA020849Baxter Hlthcare
- Aug 25, 2014NDANDA200656Fresenius Kabi Usa
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
2,059 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
Literature
Recent PubMed references pinned to Tyrosine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Real-world comparison of tirofiban versus aspirin in acute non-large-vessel occlusion ischemic stroke: A retrospective cohort study.Pakistan journal of pharmaceutical sciences · 2026 · Cui C, Meng Q, Cui C, et al.PMID 42262199DOI 10.36721/PJPS.2026.39.8.225.1
- Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.Journal of neurology · 2026 · Jander A, Bergner S, Schönwald B, et al.PMID 42260239DOI 10.1007/s00415-026-13890-2
- Anti-Photoaging and Anti-Melanogenic Effects of a Novel Lactiplantibacillus plantarum RKBP Isolated from Giant Centella asiatica.Journal of microbiology and biotechnology · 2026 · Seo J, Sung EJ, Son DY, et al.PMID 42252897DOI 10.4014/jmb.2603.03011
- Lateral hypothalamic melanin concentrating hormone-expressing neurons both promote and are required for cue-potentiated feeding.Journal of neuroendocrinology · 2026 · Raycraft LM, Mo B, Doneth A, et al.PMID 42242319DOI 10.1111/jne.70210
- Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs).Brain and behavior · 2026 · Bullecer DL, Mohammed C, Loiola JAL, et al.PMID 42219764DOI 10.1002/brb3.71520
- Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions.Clinical pharmacology in drug development · 2026 · Wang J, Xu Y, Tao Y, et al.PMID 42212550DOI 10.1002/cpdd.70071
- Long-Term Surgical Outcomes and Influential Factors of Subthalamic Nucleus Deep Brain Stimulation for Dyskinesia in Parkinson's Disease: A 3-Year Longitudinal Cohort Study.Clinical interventions in aging · 2026 · Wang S, Xue T, Ma R, et al.PMID 42205153DOI 10.2147/CIA.S600031
- [Chronic diarrhea in Parkinson's disease during Levodopa therapy].Praxis · 2026 · Macht A, Cathomas G, Bauer E, et al.PMID 42200385DOI 10.23785/PRAXIS.2026.05.006
Clinical trials
The 10 most recently updated of 2,047 ClinicalTrials.gov registrations naming Tyrosine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruiting · Phase 2 · Interventional · 108 enrolled · Curis, Inc.NCT07271667updated 2026-06-12
- A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyRecruiting · Observational · 380 enrolled · Novartis PharmaceuticalsNCT07549516updated 2026-06-12
- PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCNot yet recruiting · Phase 1 · Interventional · 396 enrolled · Hansoh BioMedical R&D CompanyNCT07645222updated 2026-06-12
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active not recruiting · Phase 1 · Phase 2 · Interventional · 190 enrolled · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT03162536updated 2026-06-12
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive not recruiting · Phase 2 · Interventional · 60 enrolled · M.D. Anderson Cancer CenterNCT04505254updated 2026-06-12
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerActive not recruiting · Phase 1 · Interventional · 36 enrolled · National Cancer Institute (NCI)NCT02503722updated 2026-06-11
- Dopaminergic Dysfunction in Late-Life DepressionCompleted · Phase 2 · Interventional · 79 enrolled · Vanderbilt University Medical CenterNCT04469959updated 2026-06-11
- Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaCompleted · Phase 2 · Interventional · 37 enrolled · Northwestern UniversityNCT02242097updated 2026-06-10
- A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyRecruiting · Phase 1 · Interventional · 40 enrolled · AstraZenecaNCT07161414updated 2026-06-10
- Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast CancerActive not recruiting · Phase 2 · Interventional · 31 enrolled · Xijing HospitalNCT05558722updated 2026-06-10
Frequently asked questions
- How does Tyrosine work?
- Mechanism-of-action class: Biological Macromolecular Activity.
- What is Tyrosine used for?
- According to FDA labeling, Tyrosine carries indications including: Slimming effect, water retention.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Tyrosine?
- Tyrosine is classified as Biological Macromolecular Activity, Metabolic Activity Alteration.
- What are the brand names for Tyrosine?
- Tyrosine is marketed under brand names including Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free.
Note. Data for
tyrosine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.